Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-02-15
DOI
10.3389/fphar.2023.1110575
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
- (2021) Lindsay N. Moreland-Head et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
- (2021) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs
- (2021) Yukari Katsuhara et al. CLINICAL DRUG INVESTIGATION
- Management of diabetes and hyperglycaemia in the hospital
- (2021) Francisco J Pasquel et al. Lancet Diabetes & Endocrinology
- Differential effects of anti‐RANKL monoclonal antibody and zoledronic acid on necrotic bone in a murine model of Staphylococcus aureus ‐induced osteomyelitis
- (2021) Hideyuki Kobayashi et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- The year in cardiovascular medicine 2021: heart failure and cardiomyopathies
- (2021) Johann Bauersachs et al. EUROPEAN HEART JOURNAL
- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions
- (2018) Nicola Kavanagh et al. CLINICAL MICROBIOLOGY REVIEWS
- Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
- (2018) Hsien-Yen Chang et al. JAMA Internal Medicine
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Data mining spontaneous adverse drug event reports for safety signals in Singapore – a comparison of three different disproportionality measures
- (2016) Pei San Ang et al. Expert Opinion On Drug Safety
- Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae
- (2016) Bonnie C Prokesch et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- A comparison of disproportionality analysis methods in national adverse drug reaction databases of China
- (2014) Yongfang Hou et al. Expert Opinion On Drug Safety
- Management of osteomyelitis of the foot in diabetes mellitus
- (2009) Fran Game Nature Reviews Endocrinology
- Does This Patient With Diabetes Have Osteomyelitis of the Lower Extremity?
- (2008) Sonia Butalia JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now